PharmaEssentia has reaffirmed its commitment to creating access to critical interferon therapies amid a reported global shortage. The Burlington, Massachusetts-based company noted a recent reported shortage of Pegasys (peginterferon alfa-2a), a treatment for hepatitis C and B. With concerns growing over drug shortages for other therapies, the company said its established cGMP manufacturing network and…